Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25C | P30307 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111890 | 0.89 | ESR1 (0.58) | ESR1ESR2HSD17B3NQO1NOX4 | |
| SCHEMBL5123944 | 0.84 | ESR1 (0.56) | ESR1ESR2HSD17B3NQO1MIF | |
| SCHEMBL27643511 | 0.83 | ESR1 (0.58) | ESR1ESR2HSD17B3NQO1MIF | |
| SCHEMBL5116838 | 0.82 | MEN1 (0.51) | ESR1ESR2NQO1KDM4EALDH1A1 | |
| SCHEMBL5111169 | 0.82 | TP53 (0.53) | ESR1ESR2HSD17B3NQO1CA9 | |
| SCHEMBL12137353 | 0.81 | ESR1 (0.47) | ESR1ESR2HSD17B3NQO1NOX4 | |
| SCHEMBL1359204 | 0.78 | HSD17B3 (0.43) | ESR1ESR2HSD17B3MIFCA9 | |
| SCHEMBL5113467 | 0.77 | NQO1 (0.49) | ESR1ESR2HSD17B3NQO1MIF | |
| SCHEMBL1357425 | 0.77 | ESR1 (0.46) | ESR1ESR2HSD17B3 | |
| SCHEMBL14277816 | 0.75 | ESR1 (0.60) | ESR1ESR2HSD17B3NQO1NOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| CN-101142203-A | Novel coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1846386-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006078833-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | ESR1 3463/4885ESR2 2401/4885HSD17B3 3296/4885 |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | KCNN2, KCNH3, KCNN1 | ESR1 226/4885ESR2 162/4885HSD17B3 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.